• 1
    Lanigan F,O'Connor D,Martin F,Gallagher WM. Molecular links between mammary gland development and breast cancer. Cell Mol Life Sci 2007; 64: 315984.
  • 2
    Yoshida R,Kimura N,Harada Y,Ohuchi N. The loss of E-cadherin, α- and β-catenin expression is associated with metastasis and poor prognosis in invasive breast cancer. Int J Oncol 2001; 18: 51320.
  • 3
    Itoh M,Bissell MJ. The organization of tight junctions in epithelia: implications for mammary gland biology and breast tumorigenesis. J Mammary Gland Biol Neoplasia 2003; 8: 44962.
  • 4
    Kominsky SL. Claudins: emerging targets for cancer therapy. Expert Rev Mol Med 2006; 8: 111.
  • 5
    Tsukita S,Furuse M,Itoh M. Multifunctional strands in tight junctions. Nat Rev Mol Cell Biol 2001; 2: 28593.
  • 6
    Morita K,Furuse M,Fujimoto K,Tsukita S. Claudin multigene family encoding four-transmembrane domain protein components of tight junction strands. Proc Natl Acad Sci USA 1999; 96: 51116.
  • 7
    Itoh M,Furuse M,Morita K,Kubota K,Saitou M,Tsukita S. Direct binding of three tight junction-associated MAGUKs. ZO-1, ZO-2, and. ZO-3, with the. COOH termini of claudins. J Cell Biol 1999; 147: 135163.
  • 8
    Itoh M,Nagafuchi A,Moroi S,Tsukita S. Involvement of ZO-1 in cadherin-based cell adhesion through its direct binding to alpha catenin and actin filaments. J Cell Biol 1997; 138: 18192.
  • 9
    Fanning AS,Jameson BJ,Jesaitis LA,Anderson JM. The tight junction protein ZO-1 establishes a link between the transmembrane protein occludin and the actin cytoskeleton. J Biol Chem 1998; 273: 2974553.
  • 10
    Tanaka M,Kamata R,Sakai R. EphA2 phosphorylates the cytoplasmic tail of Claudin-4 and mediates paracellular permeability. J Biol Chem 2005; 280: 4237582.
  • 11
    D'souza T,Indig FE,Morin PJ. Phosphorylation of claudin-4 by PKCepsilon regulates tight junction barrier function in ovarian cancer cells. Exp Cell Res 2007; 313: 336475.
  • 12
    Kominsky SL,Argani P,Korz D,Evron E,Raman V,Garrett E,Rein A,Sauter G,Kallioniemi OP,Sukumar S. Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast. Oncogene 2003; 22: 202133.
  • 13
    Cunningham SC,Kamangar F,Kim MP,Hammoud S,Haque R,Iacobuzio-Donahue CA,Maitra A,Ashfaq R,Hustinx S,Heitmiller RE,Choti MA,Lillemoe KD, et al. Claudin-4, mitogen-activated protein kinase kinase 4, and stratifin are markers of gastric adenocarcinoma precursor lesions. Cancer Epidemiol Biomarkers Prev 2006; 15: 2817.
  • 14
    Resnick MB,Gavilanez M,Newton E,Konkin T,Bhattacharya B,Britt DE,Sabo E,Moss SF. Claudin expression in gastric adenocarcinomas: a tissue microarray study with prognostic correlation. Hum Pathol 2005; 36: 88692.
  • 15
    Michl P,Buchholz M,Rolke M,Kunsch S,Lohr M,McClane B,Tsukita S,Leder G,Adler G,Gress TM. Claudin-4: a new target for pancreatic cancer treatment using Clostridium perfringens enterotoxin. Gastroenterology 2001; 121: 67884.
  • 16
    Long H,Crean CD,Lee WH,Cummings OW,Gabig TG. Expression of Clostridium perfringens enterotoxin receptors claudin-3 and claudin-4 in prostate cancer epithelium. Cancer Res 2001; 61: 787881.
  • 17
    Sheehan GM,Kallakury BV,Sheehan CE,Fisher HA,Kaufman RP,Jr,Ross JS. Loss of claudins-1 and -7 and expression of claudins-3 and -4 correlate with prognostic variables in prostatic adenocarcinomas. Hum Pathol 2007; 38: 5649.
  • 18
    Rangel LB,Agarwal R,D'souza T,Pizer ES,Alo PL,Lancaster WD,Gregoire L,Schwartz DR,Cho KR,Morin PJ. Tight junction proteins claudin-3 and claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas. Clin Cancer Res 2003; 9: 256775.
  • 19
    Pan XY,Wang B,Che YC,Weng ZP,Dai HY,Peng W. Expression of claudin-3 and claudin-4 in normal, hyperplastic, and malignant endometrial tissue. Int J Gynecol Cancer 2007; 17: 23341.
  • 20
    Konecny GE,Agarwal R,Keeney GA,Winterhoff B,Jones MB,Mariani A,Riehle D,Neuper C,Dowdy SC,Wang HJ,Morin PJ,Podratz KC. Claudin-3 and claudin-4 expression in serous papillary, clear-cell, and endometrioid endometrial cancer. Gynecol Oncol 2008; 109: 2639.
  • 21
    Kominsky SL,Vali M,Korz D,Gabig TG,Weitzman SA,Argani P,Sukumar S. Clostridium perfringens enterotoxin elicits rapid and specific cytolysis of breast carcinoma cells mediated through tight junction proteins claudin 3 and 4. Am J Pathol 2004; 164: 162733.
  • 22
    Tokes AM,Kulka J,Paku S,Szik A,Paska C,Novak PK,Szilak L,Kiss A,Bogi K,Schaff Z. Claudin-1, -3 and -4 proteins and mRNA expression in benign and malignant breast lesions: a research study. Breast Cancer Res 2005; 7: R296R305.
  • 23
    Soini Y. Claudins 2, 3, 4, and 5 in Paget's disease and breast carcinoma. Hum Pathol 2004; 35: 15316.
  • 24
    Kulka J,Szasz AM,Nemeth Z,Madaras L,Schaff Z,Molnar IA,Tokes AM. Expression of tight junction protein Claudin-4 in basal-like breast carcinomas. Pathol Oncol Res, in press.
  • 25
    Svensson S,Jirstrom K,Ryden L,Roos G,Emdin S,Ostrowski MC,Landberg G. ERK phosphorylation is linked to VEGFR2 expression and Ets-2 phosphorylation in breast cancer and is associated with tamoxifen treatment resistance and small tumours with good prognosis. Oncogene 2005; 24: 43709.
  • 26
    van de Vijver MJ,He YD,van't Veer LJ,Dai H,Hart AA,Voskuil DW,Schreiber GJ,Peterse JL,Roberts C,Marton MJ,Parrish M,Atsma D, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347: 19992009.
  • 27
    Moody SE,Perez D,Pan TC,Sarkisian CJ,Portocarrero CP,Sterner CJ,Notorfrancesco KL,Cardiff RD,Chodosh LA. The transcriptional repressor snail promotes mammary tumor recurrence. Cancer Cell 2005; 8: 197209.
  • 28
    Sorlie T,Perou CM,Tibshirani R,Aas T,Geisler S,Johnsen H,Hastie T,Eisen MB,van de Rijn M,Jeffrey SS,Thorsen T,Quist H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 1086974.
  • 29
    van 't Veer LJ,Dai H,van de Vijver MJ,He YD,Hart AA,Mao M,Peterse HL,van der Kooy K,Marton MJ,Witteveen AT,Schreiber GJ,Kerkhoven RM, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 5306.
  • 30
    Lacroix M,Leclercq G. Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res Treat 2004; 83: 24989.
  • 31
    Sommers CL,Byers SW,Thompson EW,Torri JA,Gelmann EP. Differentiation state and invasiveness of human breast cancer cell lines. Breast Cancer Res Treat 1994; 31: 32535.
  • 32
    Thompson EW,Paik S,Brunner N,Sommers CL,Zugmaier G,Clarke R,Shima TB,Torri J,Donahue S,Lippman ME, et al. Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. J Cell Physiol 1992; 150: 53444.
  • 33
    Tang S,Han H,Bajic VB. ERGDB: estrogen responsive genes database. Nucleic Acids Res 2004; 32: D533D536.
  • 34
    Cicatiello L,Scafoglio C,Altucci L,Cancemi M,Natoli G,Facchiano A,Iazzetti G,Calogero R,Biglia N,De Bortoli M,Sfiligoi C,Sismondi P, et al. A genomic view of estrogen actions in human breast cancer cells by expression profiling of the hormone-responsive transcriptome. J Mol Endocrinol 2004; 32: 71975.
  • 35
    Seth P,Porter D,Lahti-Domenici J,Geng Y,Richardson A,Polyak K. Cellular and molecular targets of estrogen in normal human breast tissue. Cancer Res 2002; 62: 45404.
  • 36
    Litkouhi B,Kwong J,Lo CM,Smedley JG, 3rd,McClane BA,Aponte M,Gao Z,Sarno JL,Hinners J,Welch WR,Berkowitz RS,Mok SC, et al. Claudin-4 overexpression in epithelial ovarian cancer is associated with hypomethylation and is a potential target for modulation of tight junction barrier function using a C-terminal fragment of Clostridium perfringens enterotoxin. Neoplasia 2007; 9: 30414.
  • 37
    Honda H,Pazin MJ,Ji H,Wernyj RP,Morin PJ. Crucial roles of Sp1 and epigenetic modifications in the regulation of the CLDN4 promoter in ovarian cancer cells. J Biol Chem 2006; 281: 2143344.
  • 38
    Singh AB,Harris RC. Epidermal growth factor receptor activation differentially regulates claudin expression and enhances transepithelial resistance in Madin-Darby canine kidney cells. J Biol Chem 2004; 279: 354352.
  • 39
    Flores-Benitez D,Ruiz-Cabrera A,Flores-Maldonado C,Shoshani L,Cereijido M,Contreras RG. Control of tight junctional sealing: role of epidermal growth factor. Am J Physiol Renal Physiol 2007; 292: F828F836.
  • 40
    Boireau S,Buchert M,Samuel MS,Pannequin J,Ryan JL,Choquet A,Chapuis H,Rebillard X,Avances C,Ernst M,Joubert D,Mottet N, et al. DNA-methylation-dependent alterations of claudin-4 expression in human bladder carcinoma. Carcinogenesis 2007; 28: 24658.
  • 41
    Agarwal R,D'souza T,Morin PJ. Claudin-3 and claudin-4 expression in ovarian epithelial cells enhances invasion and is associated with increased matrix metalloproteinase-2 activity. Cancer Res 2005; 65: 737885.
  • 42
    Michl P,Barth C,Buchholz M,Lerch MM,Rolke M,Holzmann KH,Menke A,Fensterer H,Giehl K,Lohr M,Leder G,Iwamura T, et al. Claudin-4 expression decreases invasiveness and metastatic potential of pancreatic cancer. Cancer Res 2003; 63: 626571.
  • 43
    de Oliveira SS,de Oliveira IM,De Souza W,Morgado-Diaz JA. Claudins upregulation in human colorectal cancer. FEBS Lett 2005; 579: 617985.
  • 44
    McBryan J,Howlin J,Kenny PA,Shioda T,Martin F. ERα-CITED1 co-regulated genes expressed during pubertal mammary gland development: implications for breast cancer prognosis. Oncogene 2007; 26: 640619.
  • 45
    Lechpammer M,Resnick MB,Sabo E,Yakirevich E,W OG,K TS,Tavares R,Noble LC,Delellis RA,Wang LJ. The diagnostic and prognostic utility of claudin expression in renal cell neoplasms. Mod Pathol, in press.
  • 46
    Kominsky SL,Tyler B,Sosnowski J,Brady K,Doucet M,Nell D,Smedley JG,III,McClane B,Brem H,Sukumar S. Clostridium perfringens enterotoxin as a novel-targeted therapeutic for brain metastasis. Cancer Res 2007; 67: 797782.
  • 47
    Santin AD,Cane S,Bellone S,Palmieri M,Siegel ER,Thomas M,Roman JJ,Burnett A,Cannon MJ,Pecorelli S. Treatment of chemotherapy-resistant human ovarian cancer xenografts in C.B-17/SCID mice by intraperitoneal administration of Clostridium perfringens enterotoxin. Cancer Res 2005; 65: 433442.
  • 48
    Santin AD,Bellone S,Marizzoni M,Palmieri M,Siegel ER,McKenney JK,Hennings L,Comper F,Bandiera E,Pecorelli S. Overexpression of claudin-3 and claudin-4 receptors in uterine serous papillary carcinoma: novel targets for a type-specific therapy using Clostridium perfringens enterotoxin (CPE). Cancer 2007; 109: 131222.
  • 49
    Sonoda N,Furuse M,Sasaki H,Yonemura S,Katahira J,Horiguchi Y,Tsukita S. Clostridium perfringens enterotoxin fragment removes specific claudins from tight junction strands: evidence for direct involvement of claudins in tight junction barrier. J Cell Biol 1999; 147: 195204.